KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Intangibles (2009 - 2012)

Alnylam Pharmaceuticals posted quarterly Intangibles of $145000.0 for Q3 2012, down 54.4% year-on-year from $318000.0 in Q4 2011, and down 22.87% on a QoQ basis from $188000.0 in Q2 2012.

Alnylam Pharmaceuticals (ALNY) has 4 years of Intangibles data on file, last reported at $145000.0 in Q3 2012.

  • For the quarter ending Q3 2012, Intangibles fell 54.4% year-over-year to $145000.0; the trailing twelve-month figure through Sep 2012 stood at $145000.0 (down 54.4% YoY), and the FY2011 full-year result was $275000.0, down 38.62% from the prior year.
  • Intangibles for Q3 2012 stood at $145000.0, down from $188000.0 in the prior quarter.
  • Across five years, Intangibles topped out at $622000.0 in Q4 2009 and bottomed at $145000.0 in Q3 2012.
  • The 4-year median for Intangibles is $361000.0 (2011), against an average of $365363.6.
  • The widest annual swing landed in 2010, when Intangibles decreased 27.97%; it then slumped 54.4% in 2012.
  • A 4-year view of Intangibles shows it stood at $622000.0 in 2009, then fell by 27.97% to $448000.0 in 2010, then plunged by 38.62% to $275000.0 in 2011, then sank by 47.27% to $145000.0 in 2012.
  • The last three Intangibles figures came in at $145000.0 (Q3 2012), $188000.0 (Q2 2012), and $231000.0 (Q1 2012), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Intangibles (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 4.41 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 11,640.44
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 30.30 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 418.50 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.29 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Revolution Medicines 32.39 Bn 32.39 Bn - 55.80 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2012 145,000.00
Jun 30, 2012 188,000.00
Mar 31, 2012 231,000.00
Dec 31, 2011 275,000.00
Sep 30, 2011 318,000.00
Jun 30, 2011 361,000.00
Mar 31, 2011 405,000.00
Dec 31, 2010 448,000.00
Sep 30, 2010 491,000.00
Jun 30, 2010 535,000.00
Dec 31, 2009 622,000.00